Previous 10 |
Syros Pharmaceuticals, Inc. (SYRS) Q3 2018 Results Earnings Conference Call November 01, 2018 07:30 AM ET Executives Naomi Aoki - VP, Corporate Communications and IR Dr. Nancy Simonian - CEO Dr. David Roth - Chief Medical Officer Dr. Eric Olson - Chief Scientific Officer Joe ...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present initial clinical data from both combination cohorts in its ongoing Phase 2 trial of SY-1425, its first-in-class selective retinoi...
Syros Pharmaceuticals (NASDAQ: SYRS ): Q3 GAAP EPS of -$0.47 misses by $0.01 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Opened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies Dose Escalation Data from Phase 1 Trial of ...
First Clinical Data from Phase 1 Trial of SY-1365 in Advanced Solid Tumors to be Highlighted in Oral Plenary Session Preclinical Data on Oral CDK7 Inhibitor Program to be Unveiled in Poster Session Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines tha...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial ...
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Morgan Stanley 16th Annual Global...
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cree, Inc. (NASDAQ:CREE), ArcBest Corporation (NASDAQ:ARCB), Syros Pharma...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...